Diagnostics & biosensors

01Overview and value chain#

Markers EC: 26.60 | OECD: bio-pharma | Regulator: FDA (US), EMA (EU), NMPA (CN)

Diagnostics and biosensors represent the critical first step in modern clinical pathways, converting biological signals into actionable medical data. By combining biorecognition elements (antibodies, nucleic acids, enzymes) with physicochemical transducers, these devices quantify biomarkers with extreme sensitivity. The global market, serving billions of patients, is rapidly shifting from centralized lab testing to rapid Point-of-Care (POC) molecular and genomic diagnostics, fundamentally accelerating treatment timelines and outbreak responses.

The key directions of diagnostics and biosensors are:

1. In-Vitro Diagnostics (In-Vitro Diagnostics): traditional lab-based biochemical testing of blood and tissue representing over 70% of total diagnostic volume.
2. Molecular Diagnostics (Molecular Diagnostics): analyzing DNA and RNA via PCR or sequencing to identify infectious agents and genetic mutations with 99% accuracy.
3. Point-of-Care Testing (Point-of-Care Testing): decentralized rapid testing delivering clinical-grade results in under 30 minutes at the patient’s bedside.
4. Continuous Biosensors (Continuous Biosensors): wearable patches monitoring chronic disease markers, such as continuous glucose monitors (CGMs) for millions of diabetics.

Sectoral value chain#

[Biomarker R&D] ──> [Assay Dev] ──> [Manufacturing] ──> [Clinical Dist]
                                  │
                          (Patient Data)
                                  │
                                  ▼
[Therapeutics] <─── [Clinical Dec] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Microfluidics (Lab-on-a-Chip): miniaturizing complex laboratory liquid handling into disposable plastic cartridges.
• CRISPR Diagnostics: utilizing Cas nucleases (like Cas12/Cas13) for ultra-rapid, highly specific nucleic acid detection without complex thermal cycling.
• Next-Generation Sequencing (NGS): high-throughput DNA sequencing enabling comprehensive oncology panels and non-invasive prenatal testing (NIPT).

02US#

The US dictates the global diagnostics market through dominant legacy manufacturers and a massive venture-backed ecosystem pushing POC innovations.

molecular leadership, CGM dominance, FDA pathways#

• Abbott Diagnostics: dominating the massive POC and continuous glucose monitoring (CGM) consumer markets.
• Danaher (Cepheid): leading the rapid molecular diagnostics space with its ubiquitous GeneXpert automated PCR platform.
• Hologic: leading molecular diagnostics for women’s health (HPV, STI) on its high-throughput Panther platform, plus digital breast tomosynthesis.
• FDA 510(k) & EUA: setting stringent premarket notification standards while utilizing Emergency Use Authorizations to rapidly combat pandemics.

03CN#

China is aggressively localizing its diagnostic supply chains, moving from basic lateral flow assays to high-end genomics and molecular platforms.

genomic sequencing, domestic substitution, mass screening#

• BGI Group Genomics: driving down the global cost of sequencing and executing massive state-sponsored population health screenings.
• Wondfo Biotech: scaling highly affordable POCT solutions for both domestic rural healthcare and massive export markets.
• Getein Biotech: Nanjing-based rapid POCT immunoassay maker (cardiac and inflammatory markers) scaling affordable point-of-care panels.
• Volume-Based Procurement (VBP): government-led centralized purchasing driving intense price competition and forcing out foreign legacy IVD systems.

04EU#

The EU is a stronghold of traditional microbiology and in-vitro diagnostics, currently navigating a major, disruptive regulatory overhaul.

microbiology leadership, IVDR transition, precision medicine#

• Roche Diagnostics: commanding a massive share of the global centralized clinical chemistry and immunodiagnostics market.
• bioMérieux Expertise: leading the world in clinical microbiology and rapid syndromic testing for infectious diseases.
• DiaSorin: Italian specialist in immunodiagnostics and molecular testing, running its LIAISON chemiluminescence platform across centralized labs.
• IVDR Implementation: transitioning to the stringent In Vitro Diagnostic Medical Devices Regulation (IVDR), which requires extensive clinical evidence for legacy tests.

05Leading companies and research institutes#

06Tech stack and innovations#

The modern diagnostics stack merges advanced biochemistry with precision micro-engineering and optics.

1. Multiplex Molecular Platforms:
   • Amplifies and detects dozens of distinct genetic targets (syndromic panels) simultaneously from a single patient swab.
   • Utilizes lyophilized (freeze-dried) reagents inside sealed cartridges to eliminate cold-chain logistics entirely.
2. Electrochemical Biosensors:
   • Employs immobilized enzymes (like glucose oxidase) on micro-electrodes to convert biological binding events directly into measurable electrical currents.
   • Minimizes form factors, enabling minimally invasive, 14-day wearable sensors that broadcast continuously to smartphones.
3. Digital Pathology & AI:
   • Scans traditional tissue biopsies into gigapixel digital slides.
   • Deploys deep learning algorithms to highlight malignant cells, reducing pathologist workload by 30% and eliminating human error.

07Value chains and production pipelines#

Industrial pipeline of POCT molecular diagnostics (ISO 13485)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Biomarker validation   │ ───> │ 2. Assay formulation      │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Cartridge assembly     │ <─── │ 3. Microfluidic molding   │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. QC & calibration       │ ───> │ 6. Clinical deployment    │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Biomarker validation

Identifying and validating specific nucleic acid sequences or antigens that definitively indicate the presence of a pathogen or disease state.

Stage 2: Assay formulation

Designing specific primers, probes, and enzymes, and freeze-drying them into stable reagent beads that can survive room-temperature shipping.

Stage 3: Microfluidic molding

Using precision injection molding to create intricate plastic cartridges containing microscopic channels and reaction chambers.

Stage 4: Cartridge assembly

Loading the lyophilized reagent beads into the microfluidic cartridges and hermetically sealing them under strict ISO 13485 cleanroom conditions.

Stage 5: QC & calibration

Running statistical batches of cartridges against known positive and negative clinical controls to guarantee 99%+ sensitivity and specificity.

Stage 6: Clinical deployment

Shipping the finished cartridges to decentralized clinics and emergency rooms, where patient samples are loaded directly for automated 30-minute processing.